Those who wish to gain practical tools for living optimally with rare diseases are encouraged to attend the annual Living Rare Living Stronger Patient and Family Forum, hosted by the National Organization for Rare Disorders (NORD) and set this year for June 26-27. The conference brings together patients,…
News
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for rare diseases to ensure that none of the 30 million people in Europe living with rare diseases are left behind by the start of a new decade. As part of…
The U.S. Patent and Trademark Office has issued a new patent to Strongbridge Biopharma that covers a method of using Recorlev (levoketoconazole), the company’s investigational treatment for endogenous Cushing’s syndrome, to treat people with Cushing’s who also are taking metformin for type 2 diabetes. According to a…
Some 25% of Cushing’s disease patients — or 1 in every 4 — will develop Nelson’s syndrome (NS) after surgery to remove both adrenal glands, while around 1 in every 5 will need pituitary-specific treatment, a study found. Lifelong follow-up is also needed for patients who undergo double adrenal gland…
Ahead of this year’s Rare Disease Week on Capitol Hill, held virtually July 14–22, the EveryLife Foundation will award grants to top advocates of rare disease organizations who participate in the week’s pre-events. The top 50 point-earners will be eligible to win $1,000 to $5,000in  grants, totaling up…
Symptoms of psoriasis vulgaris, an autoimmune disease that mainly affects the skin, eased in a man with cyclic Cushing’s disease during a short episode of hypercortisolemia, a period marked by cortisol levels rising above healthy limits, according to a case study.
Xeris Pharmaceuticals and Strongbridge Biopharma have entered an agreement in which Xeris will acquire Strongbridge, forming a new entity called Xeris Biopharma Holdings. Following the transaction, Xeris also will acquire Strongbridge’s pipeline, which includes Recorlev (levoketoconazole), an investigational treatment for endogenous Cushing’s syndrome. “Strongbridge’s attractive rare…
Sparrow Pharmaceuticals is planning to launch a Phase 2 clinical trial to assess the safety and effectiveness of its investigational, lead small molecule HSD-1 inhibitor, SPI-62, in people with Cushing’s syndrome. The trial is expected to open later this year, and it specifically will enroll people with ACTH-dependent Cushing’s…
Metopirone (metyrapone) safely and successfully maintained lower levels of urinary cortisol over nine months in adults with endogenous Cushing’s syndrome, according to data from the six-month extension of the PROMPT trial. Treatment with the HRA Pharma Rare Diseases…
For people with Cushing’s disease whose pituitary tumor cannot be identified, removal of one-third of the pituitary gland followed by multidisciplinary treatment and care can lead to favorable outcomes, a small study suggests. The study, “Lateral one-third gland resection in Cushing patients with failed adenoma identification…
Recent Posts
- Unexpected insulin resistance exposes rare Cushing’s disease diagnosis
- The challenges of managing Cushing’s disease during the postpartum period
- Test may be ‘practical’ alternative for diagnosing Cushing’s in kids
- Man’s aggressive salivary gland cancer triggers Cushing’s syndrome: Report
- FDA rejects relacorilant for Cushing’s-related high blood pressure
- Study supports Isturisa as first-line ectopic Cushing’s treatment
- After some scary complications, I finally gave birth to a baby girl
- Rare dual diagnosis explains man’s chronic high blood pressure: Report
- Woman with recurrent Cushing’s disease has 2 successful pregnancies
- Real-world study backs Isturisa for non-pituitary Cushing’s forms